AdjunctiveIntranasal Oxytocin Therapy for Treatmentof Negative Symptoms in Schizophrenia: ADTI Study - NI

Central Institute of Psychiatry0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年1月22日

试验速览

暂无简介。

•1) Schizophrenia diagnosed patients according to The ICD 11 Classification of Mental and Behavioural Disorders, Diagnostic criteria for research.
•2) 20–55 years of age.
•3) Disease course >2years.
•4) PANSS negative symptoms score =4 in at least four items or =15 combined.
•5) PANSS positive symptoms score=4 in at least three items or =10 combined.
•6) CDSS score <6 and SAS score <3 to rule out secondary negative symptoms.
•7) Patients receiving treatment for schizophrenia with preferably second generation anti-psychotic
•8) No substance use or addiction (except nicotine and caffeine)
•9) No medical co-morbidities.
•10) Signed informed consent.

•1) Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine.
•2) Significant medical or neurological illness including severe cardiovascular, hepatic, renal, [serum creatinine > 1.5 mg/dl], anaemia [Haemoglobin < 11 mg/dl], or myopathy or untreated thyroid disease.
•3) History of substantial brain damage or any neurological disorders.
•4) Pregnancy
•5) Allergic rhinitis or other inflammation of nasal mucosa for past 6 months
•6) Patients receiving treatment with any first-generation anti-psychotic/depot or long-acting anti-psychotic/anti-depressant.
•7) Not willing to give written informed consent.

发起方